Novo Nordisk has handed over an experimental Parkinson's disease therapy to a Mark Zuckerberg-backed AI startup. The deal aims to accelerate the treatment's development.
Novo Nordisk A/S, a major pharmaceutical company, agreed to transfer its experimental Parkinson's therapy to an AI-focused startup backed by Meta founder Mark Zuckerberg.
The move reflects a growing trend in pharma of partnering with AI companies to streamline drug development timelines. AI startups leverage machine learning algorithms to identify promising compounds, predict efficacy, and optimize clinical trial designs—capabilities that can significantly reduce development cycles.
Parkinson's disease affects millions globally, with current treatments managing symptoms rather than addressing underlying causes. Accelerating new therapeutic options remains a priority for the medical community.
Neither Novo Nordisk nor the startup disclosed specific financial terms or timelines for the therapy's development. The arrangement underscores how traditional pharmaceutical companies increasingly rely on specialized AI firms to enhance research efficiency and bring treatments to market faster.
A new project called Swiftlet enables running large language models on Apple devices with minimal resources. The tool allows an 80B parameter Qwen model on Mac and a 35B variant on iPhone.
Chinese AI companies are rapidly closing the technology gap with Silicon Valley through aggressive model launches, creating intense pressure on US competitors lacking cutting-edge capabilities or competitive pricing.
Venture capital's shift toward massive artificial intelligence investments is creating a two-tier funding landscape, with smaller firms struggling to raise capital as LPs demand returns from prior investments.